Condition: Mantle Cell Lymphoma · Sponsor: Canadian Cancer Trials Group
The purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.
This description comes directly from the study's public registry record.
Annette Hay · 613-533-6430 · ahay@ctg.queensu.ca
Laura Pearce · 613-533-6430 · lpearce@ctg.queensu.ca
Always discuss trial participation with your own doctor first.
| Cross Cancer Institute | Edmonton, Alberta, Canada | Not Yet Recruiting |
| BCCA - Vancouver | Vancouver, British Columbia, Canada | Recruiting |
| University Health Network | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07341191